HealthTree Logo
search more_vert
person Sign In / Create Account
Connect with 11;14 Myeloma Patients Today
Posted: Jan 24, 2024
Connect with 11;14 Myeloma Patients Today image

Myeloma patients with the 11;14 translocation can now share experiences, support, and accredited research with others in their same subgroup thanks to our new 11;14 HealthTree Connect Group

After joining this group (for free), you can share posts with your own personal experiences, questions, and 11;14 research that you find interesting. We invite you to connect with other 11;14 myeloma patients and learn from one another. 

Myeloma patients with the 11;14 translocation are in a unique position within the multiple myeloma world. Sometimes considered standard-risk, and other times considered intermediate-risk, they are currently the only translocation subgroup with access to precision medicine, venetoclax. This group is a place to share your experiences, accredited research, and support other patients and caregivers dealing with 11;14 myeloma. Start your post today! 

11;14 Myeloma Translocation Group

Note: If you have not yet joined HealthTree Connect, you will be asked to complete a short profile before joining the 11;14 group. If you have any questions, reach out to or call/text +1 800 709 1113. 

11;14 Myeloma Translocation Resources

How to Determine Whether or Not a Stem Cell Transplant is Successful with Dr. Guido Tricot

In this article, you can read how Dr. Guido Tricot shares about 11;14 as a low/standard risk translocation. He also shares his personal observation that 11;14 patients have the hardest time achieving MRD negativity. You can watch the entire recording here: Dr. Guido Tricot SCT Recording

ASH 2023: Using Venetoclax with 11;14 Myeloma Patients

11;14 myeloma patient, Todd Kennedy, shares the latest research on venetoclax use for 11;14 patients as presented at the 2023 American Society of Hematology (ASH) conference. He also shares some personal insights as an 11;14 patient. 

HealthTree University Venetoclax Unit 

Learn more about venetoclax in our HealthTree University Class. This medicine is the only "precision medicine" currently being used in myeloma, even though it's not currently FDA-approved for general myeloma treatment use. 

Understanding FISH, Genomics, and Myeloma Genetics Webinar

Dr. Attaya Suvannasankha recently taught our community about FISH testing, results, and myeloma genetics. Learn more from her excellently explained webinar above. 

The author Audrey Burton-Bethke

about the author
Audrey Burton-Bethke

Audrey is the Editor for the HealthTree Foundation for Multiple Myeloma. She originally joined the HealthTree Foundation in 2020 as the Myeloma Community Program Director. While not knowing much about myeloma initially, she worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys iced chais from Dutch Bros. She also loves spending time with her supportive husband and energetic three-year-old. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube